X.T.L. Biopharmaceuticals Ltd. XTLB-IL:Tel Aviv Stock Exchange

*Data is delayed | Exchange | ILS
Last | 5:13 PM EEST
9.30quote price arrow down-0.20 (-2.08%)
Volume
1,146,887
52 week range
3.10 - 17.10
Loading...
  • Open9.40
  • Day High9.80
  • Day Low9.30
  • Prev Close9.40
  • 52 Week High17.10
  • 52 Week High Date03/25/24
  • 52 Week Low3.10
  • 52 Week Low Date01/25/24

Key Stats

  • Market Cap13.95M
  • Shares Out544.91M
  • 10 Day Average Volume2.32M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change165.71

KEY STATS

  • Open9.40
  • Day High9.80
  • Day Low9.30
  • Prev Close9.40
  • 52 Week High17.10
  • 52 Week High Date03/25/24
  • 52 Week Low3.10
  • 52 Week Low Date01/25/24
  • Market Cap13.95M
  • Shares Out544.91M
  • 10 Day Average Volume2.32M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change165.71

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On X.T.L. Biopharmaceuticals Ltd.

 

Content From Our Affiliates

Profile

MORE
XTL Biopharmaceuticals Ltd is an Israel-based biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and...
Doron Turgeman
Non-Executive Chairman of the Board
Shlomo Shalev
Chief Executive Officer, Director
Itay Weinstein
Chief Financial Officer
Address
5 Badner St.,
P.O.Box 8241
Ramat Gan, NY
5218102
Israel